missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ BCAR3 Polyclonal Antibody

Description
Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 μg/mL. Positive Control - WB: HEPG2 whole cell. IHC: mouse lymphaden tissue, rat spleen tissue, human tonsil tissue.
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48.
Specifications
Specifications
| Antigen | BCAR3 |
| Applications | Immunohistochemistry (Paraffin), Western Blot |
| Classification | Polyclonal |
| Concentration | 500 μg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 5mg BSA and 0.05mg sodium azide |
| Gene | BCAR3 |
| Gene Accession No. | O75815, Q9QZK2 |
| Gene Alias | AI131758; And34; AND-34; Bcar3; breast cancer anti-estrogen resistance 3; breast cancer antiestrogen resistance 3 protein; breast cancer anti-estrogen resistance protein 3; dJ1033H22.2 (breast cancer anti-estrogen resistance 3); KIAA0554; novel SH2-containing protein 2; NSP2; OTTHUMP00000011961; p130Cas-binding protein AND-34; SH2 domain-containing protein 3B; SH2D3B; UNQ271/PRO308 |
| Gene Symbols | BCAR3 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?